FDA Inspection 1205857 — Pieter Jan Berghmans
The FDA completed an inspection of Pieter Jan Berghmans on May 5, 2023 in Edegem. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- May 5, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Edegem (Belgium)
Additional Details
Clinical BA/BE